Earnings release
Page 1
RNS Trading Statement PRELIMINARY FOURTH QUARTER 2025 FINANCIAL RESULTS CELLBXHEALTH PLC Released 07:00:06 16 January 2026 RNS Number : 1444P CelLBxHealth PLC 16 January 2026 CelLBxHealth plc ("the Company") Preliminary Fourth Quarter 2025 Financial Results Guildford, UK and Plymouth Meeting, US - 16 January 2026 - CelLBxHealth plc (A circulating tumour cell (CTC) intelligence, with tests and services supporting research, clinical oncology, announces an update on 2025 unaudited financial results and further c looks to drive commercial progress in 2026. Preliminary 2025 financial results The Company now expects to report fourth quarter and full year 2025 revenues of approxi £1.4 million respectively. The full year biopharma and product revenues were £0.3 m respectively. The Company was expecting to achieve revenues of £1.6million for the ye 2025, however a few sales contracts, with an aggregate value of approximately £0.2 million first quarter of 2026. Cash at 31 December 2025 was £7.3 million, providing a strong balance sheet from which strategy. Cost rationalisation The Company is reducing costs at all levels and consequently has voluntarily delisted i trading on the OTCQX Market due to low trading volume and the associated administra Company's last day of trading on the OTCQX Market was 31 December 2025. Beginni Company has transitioned to trading on the Pink Limited Market. The Company is also rationalising its operations at Guildford into one facility. Along wit and other restructuring activities, total cost savings are expected to be approximately £5.9 m basis. Outlook for 2026
Page 2
Further to the fundraising announced in late November 2025, the Company is now pursu strategy, focused on the delivery of commercial milestones from its qualified 202 approximately £12.6 million (risk weighted pipeline of £4.5 million), which underpins its re 2026 Reporting Calendar · April 2026: Q1 2026 financial results and business update · June 2026: preliminary FY2025 financial results · June 30, 2026: Annual general shareholders' meeting · July 2026: Q2 2026 financial results and business update · November 2026: Q3 2026 financial results and business update Financial information and auditor review The preliminary unaudited financial information for the year ended 31 December 2025 prepared from the Company's internal management accounts. The Company has not yet fin year ended 31 December 2025. Accordingly, the final audited results may differ from the financial information presented above, and such differences may be material. Peter Collins CEO of CelLBxHealth commented: 'The Company remains on track with the execution of its organisational restructure and cost-saving measures. With management focused on refining the Company's business str and implementing the restructure during the fourth quarter of 2025, some sales contracts, w of approximately £0.2 million, were deferred into the first quarter of 2026.' For further information: CelLBxHealth plc Peter Collins, Chief Executive Officer +44 (0) 1483 343434 investor@cellbxhealth.com Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper (Corporate Finance) Sunila de Silva (Corporate Broking) Nigel Birks (Life Science Specialist Sales) +44 (0) 20 7220 0500 FTI Consulting Simon Conway, Ciara Martin, Sam Purewal +44 (0) 203 727 1000 The information contained within this announcement is deemed by the Company to constitu stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of UK domes European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announc information service, this information is considered to be in the public domain. Notes for editors About CelLBxHealth plc
Page 3
CelLBxHealth plc is a precision CTC intelligence company specialising in innovative (CTC) solutions for use in research, drug development and clinical oncology. Its pate platform harvests CTCs from blood and can be integrated with existing laboratory instrum downstream analysis - including whole-cell imaging, proteomic profiling and full genomic Commercial activities centre on (1) Product Sales: Accelerating Parsortix platform adoptio through CROs and clinical lab partnerships. (2) Laboratory services: Clinical trial support (3) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused programme. The product portfolio comprises the Parsortix® platform with associated consumables services are delivered from CelLBxHealth's GCLP compliant UK laboratory, providin support and assay development. For more information, visit https://cellbxhealth.com/. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply. © 2026 London Stock Exchange plc. All rights reserved.